Foresee Pharmaceuticals is making great strides forward. Chairman Ben Chien said recently that the global market share of its prostate cancer drug in new dosage, CAMCEVI, will challenge 10% of global market share by the end of the year. With the launch of 3-month dosage form in 2025, the market share will be boosted by the two products. The company is planning to start licensing in 2024 for the treatment of central precocious puberty. Internally, Foresee has set a target of 2 billion to 3 billion US dollars in market value within 5 years, a tenfold increase compared to the existing one.

The three-month dose is expected to be marketed in 2024 after the completion of batch scaling up and safety testing, and is expected to be licensed in the US in 2025, Chien added.

In addition, the 6-month dose has now been expanded to include central precocious puberty. The product costs US$20,000 per dose in the US, more than 20 times the price of prostate cancer, and has a compound annual growth rate of 9%. The clinical trial is open-lable and more information is expected to be available in 2024, at which time licensing will be initiated, possibly with existing licensing partners or new partners.

According to CFO Max Chan, the six-month dose of CAMCEVI is used by approximately 150,000 to 200,000 doses per year in the US market. According to the latest Centers for Medicare and Medicaid Services (CMS) data, the average selling price (ASP) of CAMCEVI is more than three times that of other similar products available. This ASP, which includes a portion sold to wholesalers at close to the WAC (Wholesale Acquisition Cost) of US$3,900, is expected to apply in 2023 and will be reflected in revenue at that time.

The company is aimed at stable long-term revenue and a balanced product portfolio of high-risk, high-reward new drugs, and now pharmaceutical sales will gradually increase, bringing long-term contributions and momentums for better new drugs to accelerate the expansion of operations.